Cargando…
Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
HMG-CoA reductase (HMGR), a rate-limiting enzyme of the mevalonate pathway in Gram-positive pathogenic bacteria, is an attractive target for development of novel antibiotics. In this study, we report the crystal structures of HMGR from Enterococcus faecalis (efHMGR) in the apo and liganded forms, hi...
Autores principales: | Bose, Sucharita, Steussy, C. Nicklaus, López-Pérez, Daneli, Schmidt, Tim, Kulathunga, Samadhi C., Seleem, Mohamed N., Lipton, Mark, Mesecar, Andrew D., Rodwell, Victor W., Stauffacher, Cynthia V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070635/ https://www.ncbi.nlm.nih.gov/pubmed/37012403 http://dx.doi.org/10.1038/s42003-023-04639-y |
Ejemplares similares
-
The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases
por: Friesen, Jon A, et al.
Publicado: (2004) -
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016) -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2015) -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2014) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023)